Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

By N. Chen, W. Fang, J. Zhan, Shaodong Hong, Yanna Tang, Shiyang Kang, Yaxiong Zhang, Xiaobo He, Ting Zhou, T. Qin and 3 more. Journal of Thoracic Oncology, 2015

637 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/6e72644c5d7d57803aff6eecbf12178a5a02f13b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Xu Dong Zhang
2. Lei Jin
3. Jiezhong Chen
4. C. Jiang

Citations in the corpus

• Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma (2016, background): “435 Besides, EGFR mutation didn’t increased the expression of PD-L1 like others reported but 436 with a relatively lower expression than TP53 and KRAS mutation(45), which further 437”
• Regulatory mechanisms of PD-1/PD-L1 in cancers (2024, methodology): “If using EGFR-TKI to inhibit EGFR, it can suppress PD-L1 expression and reac-tivate anti-tumor immunity in T cells [397].”
• Regulation of PD-L1: a novel role of pro-survival signalling in cancer. (2016, background): “Chen N, Fang W, Zhan J et al. Up-regulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.”